Literature DB >> 20442639

CD8-positive primary cutaneous anaplastic large T-cell lymphoma (PCALCL): case report and review of this unusual variant of PCALCL.

Jose A Plaza1, Pablo Ortega, James Lynott, Michael Mullane, Steve Kroft, Horatiu Olteanu.   

Abstract

Primary cutaneous anaplastic large T-cell lymphoma (PCALCL) is a well-defined CD30-positive lymphoproliferative disorder with relatively good prognosis and response to treatment. We describe a case of PCALCL expressing CD8. The patient is a 57-year-old man that clinically presented with an ulcerated nodule in his left middle finger. Histopathologic sections showed an ulcerated epidermis with a diffuse lymphocytic infiltrate in the superficial dermis with focal epidermotropism. The large cohesive atypical cells were admixed with a reactive infiltrate composed of neutrophils, eosinophils, and small lymphocytes. Immunohistochemical studies showed the tumor cells to be strongly positive for CD8, CD30, and TIA-1, focally positive for CD3, and negative for CD4, CD20, CD56, Anaplastic Lymphoma Kinase (ALK-1), and HSV. Epstein-Barr virus by in situ hybridization was negative. The diagnosis of a CD8+ PCALCL was confirmed. There is limited precedent literature regarding CD8-positive PCALCL and this case falls within the clinical and histopathologic spectrum of CD30+ lymphoproliferative disorders. CD8/CD30 coexpression is rare in PCALCL and may have important clinical and prognostic implications. To the best of our knowledge there are only 4 previously reported cases describing similar findings.

Entities:  

Mesh:

Year:  2010        PMID: 20442639     DOI: 10.1097/DAD.0b013e3181c57ec2

Source DB:  PubMed          Journal:  Am J Dermatopathol        ISSN: 0193-1091            Impact factor:   1.533


  1 in total

1.  Primary Cutaneous CD8(+) CD30(+) Anaplastic Large Cell Lymphoma: An Unusual Case with a High Ki-67 index-A Short Review.

Authors:  Jitendra G Nasit; Smita C Patel
Journal:  Indian J Dermatol       Date:  2015 Jul-Aug       Impact factor: 1.494

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.